| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Application for quotation of securities - TRJ
|
8 Apr 2025 10:21AM |
$0.740 |
$0.260 |
fallen by
64.86%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Change in substantial holding
|
13 Mar 2025 4:23PM |
$0.900 |
$0.260 |
fallen by
71.11%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
H1 FY25 Financial Results Presentation
|
27 Feb 2025 8:09AM |
$0.830 |
$0.260 |
fallen by
68.67%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Record revenue achieved in H1 FY25 of $81.0 million.
- nEBITDA increased to $7.9 million from $4.0 million in the previous year.
- Components & Consumables revenue grew by 15-20% over the previous corresponding period.
- Capital Equipment order book increased by $2.4 million.
- Investment in disruptive technologies continues with planned commercial launches.
- Financial guidance for FY25 maintained with a focus on margin improvement.
- Strong customer demand momentum and order book supporting growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
H1 FY25 Financial Results Release
|
27 Feb 2025 8:09AM |
$0.830 |
$0.260 |
fallen by
68.67%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Group Net Revenue $81.0M, up 6.0% on previous corresponding period.
- Components & Consumables segment $48.9M, up 4.9%.
- Capital Equipment segment $29.9M, up 8.1%.
- Group Normalised EBITDA $7.9M, up 97.2%.
- Operating NPATA of $1.0M.
- Net Debt decreased by $2.3M to $30.6M.
- Guidance maintained for FY25 Net Revenue of $160.0M to $165.0M.
- Customer demand showed strong growth compared to H1FY24.
- Investment in Disruptive Technologies expected to be around $1.0M.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
H1 FY25 Appendix 4D and Interim Report
|
27 Feb 2025 8:08AM |
$0.830 |
$0.260 |
fallen by
68.67%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Trajan Group's revenue for H1 FY25 was $81.0 million, a 6% increase from H1 FY24.
- The company reported a net loss of $3.5 million for the period.
- Strong organic growth was observed in the Components and Consumables segment.
- Trajan emphasizes the importance of reliable analytical data for human health.
- The company has invested significantly in its manufacturing capabilities in Malaysia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
FY25 Half Year Results and Investor Webcast Notification
|
3 Feb 2025 9:32AM |
$0.920 |
$0.260 |
fallen by
71.74%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Application for quotation of securities - TRJ
|
2 Jan 2025 4:10PM |
$1.000 |
$0.260 |
fallen by
74%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Change of Director's Interest Notice
|
24 Dec 2024 8:21AM |
$1.020 |
$0.260 |
fallen by
74.51%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Change of Director's Interest Notice
|
25 Nov 2024 12:42PM |
$0.905 |
$0.260 |
fallen by
71.27%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Change of Director's Interest Notice
|
20 Nov 2024 3:18PM |
$1.020 |
$0.260 |
fallen by
74.51%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Change of Director's Interest Notice
|
20 Nov 2024 3:17PM |
$1.020 |
$0.260 |
fallen by
74.51%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Change of Director's Interest Notice
|
20 Nov 2024 3:17PM |
$1.020 |
$0.260 |
fallen by
74.51%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Change of Director's Interest Notice
|
20 Nov 2024 3:16PM |
$1.020 |
$0.260 |
fallen by
74.51%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Notification regarding unquoted securities - TRJ
|
20 Nov 2024 3:07PM |
$1.020 |
$0.260 |
fallen by
74.51%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Results of 2024 Annual General Meeting
|
29 Oct 2024 12:02PM |
$1.260 |
$0.260 |
fallen by
79.37%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Business Update
|
29 Oct 2024 9:13AM |
$1.200 |
$0.260 |
fallen by
78.33%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Total Net Revenue up high single digit over prior comparative period.
- Capital Equipment food sector demonstrating strong growth contributing to total Segment revenue up 15% in Q1 over prior comparative period.
- Order demand increasing for Trajan’s MOSH/MOAH food safety instrument systems.
- US FDA purchased Trajan’s MOSH/MOAH instrument system in Q1.
- Pharmaceutical Sector continues to be soft.
- Single digit growth in Components and Consumables over prior comparative period.
- FY2025 Guidance maintained; Net Revenue of $160.0M to $165.0M, Group nEBITDA of $17.0 to $19.0M.
- Completion of small acquisition of Mass Spec Studio data processing software platform from University of Calgary.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
2024 Annual General Meeting Chair Address and Presentation
|
29 Oct 2024 9:10AM |
$1.200 |
$0.260 |
fallen by
78.33%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Notification regarding unquoted securities - TRJ
|
28 Oct 2024 10:05AM |
$1.210 |
$0.260 |
fallen by
78.51%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
2024 Notice of Annual General Meeting
|
26 Sep 2024 5:22PM |
$1.250 |
$0.260 |
fallen by
79.20%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Change in substantial holding
|
20 Sep 2024 5:21PM |
$1.245 |
$0.260 |
fallen by
79.12%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Change of Director's Interest Notice
|
3 Sep 2024 11:30AM |
$1.200 |
$0.260 |
fallen by
78.33%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Application for quotation of securities - TRJ
|
3 Sep 2024 11:25AM |
$1.200 |
$0.260 |
fallen by
78.33%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
2024 Annual General Meeting
|
29 Aug 2024 8:06AM |
$1.150 |
$0.260 |
fallen by
77.39%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
FY24 Appendix 4G and Corporate Governance Statement
|
29 Aug 2024 8:06AM |
$1.150 |
$0.260 |
fallen by
77.39%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
FY24 Financial Results Presentation
|
29 Aug 2024 8:06AM |
$1.150 |
$0.260 |
fallen by
77.39%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Extraordinary industry-wide issues impacted TRJ’s FY24 result, particularly during H1 with destocking in the Components & Consumables Segment, and in H2 with a slowdown in pharmaceutical sector capital equipment orders.
- Net revenue was slightly down with $155.0M in FY24 compared to $162.2M in FY23.
- nEBITDA Core decreased from $23.9M in FY23 to $17.2M in FY24.
- Commercialization of products within the Disruptive Technologies segment is progressing, with the Microsampling portfolio to be nEBITDA breakeven in FY25.
- Net profit after tax plus amortization (NPATA) was $0.6M in FY24, down from $5.8M in FY23.
- Proforma Gross Margin decreased slightly from 43.2% in FY23 to 41.1% in FY24 due to under-utilization of manufacturing infrastructure.
- Revenue and nEBITDA in H2 showed improvement over H1, returning to growth.
- Financial guidance for the upcoming year includes expected net revenue of $160.0M-$165.0M and nEBITDA of $17.0M-$19.0M.
- The company anticipates Components & Consumables to continue at historical growth rates post-destocking, and Capital Equipment demand within the pharmaceutical sector to return to typical order demand in CY25.
- Trajan Group Holdings Limited emphasizes a robust business model, high barriers to market entry, and long-term shareholder value focus.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.